Drug-eluting stents studies in mice: Do we need atherosclerosis to study restenosis?

Vascular Pharmacology

Volumn 44, Issue 5, 2006, Pages 257-264

  Pires, Nuno M M ^a,b   Jukema, J Wouter ^b   Daemen, Mat J A P ^c   Quax, Paul H A ^a,b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

(Histo)Pathology; Animal models; Atherosclerosis; Drug eluting stents; Restenosis

Indexed keywords

7 HEXANOYLTAXOL; DACTINOMYCIN; DEXAMETHASONE; EVEROLIMUS; PACLITAXEL; PACLITAXEL DERIVATIVE; QP 2; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; DRUG SAFETY; EVALUATION; HEALING IMPAIRMENT; HUMAN; HYPERSENSITIVITY REACTION; IN-STENT RESTENOSIS; MOUSE STRAIN; NONHUMAN; PAIN; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; RESTENOSIS; REVIEW; SIDE EFFECT; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; PACLITAXEL; SIROLIMUS; STENTS;

EID: 33646133403     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.01.011     Document Type: Review

References (57)

1. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., Wild D.H., Brehm B.R., Riessen R., Koveker G., and Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
2. Bauters C., Meurice T., Hamon M., McFadden E., Lablanche J.M., and Bertrand M.E. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc. Res. 31 (1996) 835-846
3. Breslow J.L. Mouse models of atherosclerosis. Science 272 (1996) 685-688
4. Carmeliet P., Moons L., Stassen J.M., de Mol M., Bouche A., van den Oord J.J., Kockx M., and Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am. J. Pathol. 150 (1997) 761-776
5. Carmeliet P., Moons L., and Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc. Res. 39 (1998) 8-33
6. Creel C.J., Lovich M.A., and Edelman E.R. Arterial paclitaxel distribution and deposition. Circ. Res. 86 (2000) 879-884
7. Drachman D.E., Edelman E.R., Seifert P., Groothuis A.R., Bornstein D.A., Kamath K.R., Palasis M., Yang D., Nott S.H., and Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36 (2000) 2325-2332
8. Farb A., Heller P.F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., Scott D.S., Froehlich J., and Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
9. Farb A., John M., Acampado E., Kolodgie F.D., Prescott M.F., and Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 106 (2002) 2379-2384
10. Finn A.V., Kolodgie F.D., Harnek J., Guerrero L.J., Acampado E., Tefera K., Skorija K., Weber D.K., Gold H.K., and Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
11. Fischer J.W. Dexamethasone: effects on neointimal hyperplasia and vessel integrity. Cardiovasc. Res. 68 (2005) 350-352
12. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M., Cleman M., Heuser R., Almond D., Teirstein P.S., Fish R.D., Colombo A., Brinker J., Moses J., Shaknovich A., Hirshfeld J., Bailey S., Ellis S., Rake R., Goldberg S., and for The Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331 (1994) 496-501
13. Grube E., Sonoda S., Ikeno F., Honda Y., Kar S., Chan C., Gerckens U., Lansky A.J., and Fitzgerald P.J. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109 (2004) 2168-2171
14. Hickey T., Kreutzer D., Burgess D.J., and Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J. Biomed. Mater. Res. 61 (2002) 180-187
15. Hoffmann R., Langenberg R., Radke P., Franke A., Blindt R., Ortlepp J., Popma J.J., Weber C., and Hanrath P. Evaluation of a high-dose dexamethasone-eluting stent. Am. J. Cardiol. 94 (2004) 193-195
16. Honda Y., Grube E., de La Fuente L.M., Yock P.G., Stertzer S.H., and Fitzgerald P.J. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 104 (2001) 380-383
17. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., and Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92 (1993) 883-893
18. Kataoka T., Grube E., Honda Y., Morino Y., Hur S.H., Bonneau H.N., Colombo A., Di Mario C., Guagliumi G., Hauptmann K.E., Pitney M.R., Lansky A.J., Stertzer S.H., Yock P.G., and Fitzgerald P.J. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 106 (2002) 1788-1793
19. Kumar A., Hoover J.L., Simmons C.A., Lindner V., and Shebuski R.J. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 96 (1997) 4333-4342
20. Landau C., Lange R.A., and Hillis L.D. Percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 330 (1994) 981-993
21. Lansky A.J., Costa R.A., Mintz G.S., Tsuchiya Y., Midei M., Cox D.A., O'Shaughnessy C., Applegate R.A., Cannon L.A., Mooney M., Farah A., Tannenbaum M.A., Yakubov S., Kereiakes D.J., Wong S.C., Kaplan B., Cristea E., Stone G.W., Leon M.B., Knopf W.D., O'Neill W.W., and DELIVER Clinical Trial Investigators. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109 (2004) 1948-1954
22. *3Leiden transgenic mice. Circ. Res. 87 (2000) 248-253
23. Liistro F., Stankovic G., Di Mario C., Takagi T., Chieffo A., Moshiri S., Montorfano M., Carlino M., Briguori C., Pagnotta P., Albiero R., Corvaja N., and Colombo A. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105 (2002) 1883-1886
24. Lindner V., Fingerle J., and Reidy M.A. Mouse model of arterial injury. Circ. Res. 73 (1993) 792-796
25. Liu X., Huang Y., Hanet C., Vandormael M., Legrand V., Dens J., Vandenbossche J.L., Missault L., Vrints C., and de Scheerder I. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter. Cardiovasc. Interv. 60 (2003) 172-178
26. Mintz G.S., Popma J.J., Pichard A.D., Kent K.M., Satler L.F., Wong C., Hong M.K., Kovach J.A., and Leon M.B. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94 (1996) 35-43
27. Monraats P.S., Pires N.M., Schepers A., Agema W.R., Boesten L.S., de Vries M.R., Zwinderman A.H., de Maat M.P., Doevendans P.A., de Winter R.J., Tio R.A., Waltenberger J., Hart L.M.'t., Frants R.R., Quax P.H., van Vlijmen B.J., Havekes L.M., van der Laarse A., van der Wall E.E., and Jukema J.W. Tumor necrosis factor-α plays an important role in restenosis development. FASEB J. 19 (2005) 1998-2004
28. Morice M.C., Serruysm P.W., Sousam J.E., Fajadetm J., Ban-Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R., and RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346 (2002) 1773-1780
29. Moroi M., Zhang L., Yasuda T., Virmani R., Gold H.K., Fishman M.C., and Huang P.L. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J. Clin. Invest. 101 (1998) 1225-1232
30. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349 (2003) 1315-1323
31. Muller W., and Crothers D.M. Studies of the binding of actinomycin and related compounds to DNA. J. Mol. Biol. 35 (1968) 251-290
32. Paigen B., Plump A.S., and Rubin E.M. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr. Opin. Lipidol. 5 (1994) 258-264
33. Park S.J., Shim W.H., Ho D.S., Raizner A.E., Park S.W., Hong M.K., Lee C.W., Choi D., Jang Y., Lam R., Weissman N.J., and Mintz G.S. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348 (2003) 1537-1545
34. Perin E.C. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. Rev. Cardiovasc. Med. 6 (2005) S13-S21
35. Pires N.M., van der Hoeven B.L., de Vries M.R., Havekes L.M., van Vlijmen B.J., Hennink W.E., Quax P.H., and Jukema J.W. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(ε-caprolactone) stent cuff. Biomaterials 26 (2005) 5386-5394
36. Pires N.M., Schepers A., van der Hoeven B.L., de Vries M.R., Boesten L.S., Jukema J.W., and Quax P.H. Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. Cardiovasc. Res. 68 (2005) 215-224
37. Quax P.H., Lamfers M.L., Lardenoye J.H., Grimbergen J.M., de Vries M.R., Slomp J., de Ruiter M.C., Kockx M.M., Verheijen J.H., and van Hinsbergh V.W. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 103 (2001) 562-569
38. Reil T.D., Sarkar R., Kashyap V.S., Sarkar M., and Gelabert H.A. Dexamethasone suppresses vascular smooth muscle cell proliferation. J. Surg. Res. 85 (1999) 109-114
39. Roque M., Fallon J.T., Badimon J.J., Zhang W.X., Taubman M.B., and Reis E.D. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler. Thromb. Vasc. Biol. 2 (2000) 335-342
40. Rowinsky E.K., and Donehower R.C. Paclitaxel (taxol). N. Engl. J. Med. 332 (1995) 1004-1014
41. Sata M., Maejima Y., Adachi F., Fukino K., Saiura A., Sugiura S., Aoyagi T., Imai Y., Kurihara H., Kimura K., Omata M., Makuuchi M., Hirata Y., and Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J. Mol. Cell. Cardiol. 32 (2000) 2097-2104
42. Schuler W., Sedrani R., Cottens S., Haberlin B., Schulz M., Schuurman H.J., Zenke G., Zerwes H.G., and Schreier M.H. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
43. Schwartz R.S., Edelman E.R., Carter A., Chronos N., Rogers C., Robinson K.A., Waksman R., Weinberger J., Wilensky R.L., Jensen D.N., Zuckerman B.D., Virmani R., and Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
44. Schwartz R.S., Chronos N.A., and Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J. Am. Coll. Cardiol. 44 (2004) 1373-1385
45. Schwartz R.S., Edelman E.R., Carter A., Chronos N.A., Rogers C., Robinson K.A., Waksman R., Machan L., Weinberger J., Wilensky R.L., Goode J.L., Hottenstein O.D., Zuckerman B.D., and Virmani R. Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation 110 (2004) 2498-2505
46. Serruys P.W., Ormiston J.A., Sianos G., Sousa J.E., Grube E., den Heijer P., de Feyter P., Buszman P., Schomig A., Marco J., Polonski L., Thuesen L., Zeiher A.M., Bett J.H., Suttorp M.J., Glogar H.D., Pitney M., Wilkins G.T., Whitbourn R., Veldhof S., Miquel K., Johnson R., Coleman L., Virmani R., and ACTION investigators. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J. Am. Coll. Cardiol. 44 (2004) 1363-1367
47. Sousa J.E., Costa M.A., Abizaid A., Abizaid A.S., Feres F., Pinto I.M., Seixas A.C., Staico R., Mattos L.A., Sousa A.G., Falotico R., Jaeger J., Popma J.J., and Serruys P.W. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103 (2001) 192-195
48. Spencer C.M., Goa K.L., and Gillis J.C. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54 (1997) 925-975
49. van den Maagdenberg A.M., Hofker M.H., Krimpenfort P.J., de Bruijn I., van Vlijmen B., van der Boom H., Havekes L.M., and Frants R.R. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268 (1993) 10540-10545
50. van der Hoeven B.L., Pires N.M., Warda H.M., Oemrawsingh P.V., van Vlijmen B.J., Quax P.H., Schalij M.J., van der Wall E.E., and Jukema J.W. Drug-eluting stents: results, promises and problems. Int. J. Cardiol. 99 (2005) 9-17
51. Vink A., Schoneveld A.H., van der Meer J.J., van Middelaar B.J., Sluijter J.P., Smeets M.B., Quax P.H., Lim S.K., Borst C., Pasterkamp G., and de Kleijn D.P. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106 (2002) 1985-1990
52. Virmani R., Liistro F., Stankovic G., Di Mario C., Montorfano M., Farb A., Kolodgie F.D., and Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
53. Virmani R., Kolodgie F.D., Farb A., and Lafont A. Drug eluting stents: are human and animal studies comparable?. Heart 89 (2003) 133-138
54. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., Mihalcsik L., Tespili M., Valsecchi O., and Kolodgie F.D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
55. Virmani R., Farb A., Guagliumi G., and Kolodgie F.D. Drug-eluting stents: caution and concerns for long-term outcome. Coron. Artery Dis. 15 (2004) 313-318
56. Wieneke H., Dirsch O., Sawitowski T., Gu Y.L., Brauer H., Dahmen U., Fischer A., Wnendt S., and Erbel R. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter. Cardiovasc. Interv. 60 (2003) 399-407
57. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471